ACR 2020 Reproductive Guidelines - Medication Use with Pregnancy (Best of 2020)
Editor's note: This article originally appeared September 9, 2020, and is being shared again as part of RheumNow's "Best of 2020". We hope you enjoy reading it again.
ACR 2020 Reproductive Guidelines - Lactation Guidance (Best of 2020)
Editor's note: This article originally appeared September 10, 2020, and is being shared again as part of RheumNow's "Best of 2020" coverage.
Best of 2020: ACR 2020 Reproductive Guidelines - Contraception & Counseling
Editor's note: this article originally appeared September 8, 2020 and is being shared again as part of RheumNow's "Best of 2020".
Best of 2020: The COVID-19 Global Rheumatology Registry
Editor's note: This article originally appeared March 17, 2020 and is being shared again as a "Best of 2020".
As the highly virulent SARS-CoV-2 spreads over the world, uncertainty and fear for our patients with rheumatic diseases mount.
Best of 2020: A Rheumatologist’s Tips: Telemedicine in 6 Easy Steps
Editor's note: This article originally appeared March 18, 2020, and is being shared again as "Best of 2020" for your reading pleasure.
Ready for Telemedicine/Telerheumatology?
Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)
Editor's note: This article originally appeared May 18, 2020, and is being shared again as a "Best of 2020" article as we wrap up this year.
Lung Cancer Survival With Autoimmune Disease
Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
Rheumatic Disease and COVID-19: Who Is at Risk?
MedPage Today
Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.
RheumNow Podcast – Back Talk Listener Questions (12.04.20)
Dr Jack Cush takes questions from RheumNow listeners
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
ACR20 - Day 3 Report
Here are my highlights from day three, Sunday, of the ACR 2020 Convergence.
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Social
Updates on Reproductive Health in Women with SLE
https://t.co/E09cvQbVoD
#ACR22 https://t.co/Ausa6ELoHe
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 1 month ago
Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
Richard Conway @RichardPAConway ( View Tweet )
3 years 1 month ago
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Mike Putman @EBRheum ( View Tweet )
3 years 1 month ago
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 1 month ago
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Eric Dein @ericdeinmd ( View Tweet )
3 years 1 month ago
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 1 month ago
